| Intercytex is the leading developer of
regenerative medicine products to restore skin and |
 |
|
hair. Intercytex uses its fully integrated cell
technology platform to develop living, human cell-based
products, at commercially viable scale in attractive
markets.
Intercytex has four products in development:
|
|
All Intercytex' products are derived from unmodified human
cells.
Intercytex commenced operations in 2000 and currently employs
around 80 staff. In addition to its head office in Cambridge, UK,
it has GMP compliant clinical production facility
plus research and development laboratories in Manchester,
UK. Additional laboratories are located in Boston, USA.
Intercytex’ shares trade on the Alternative
Investment Market of the London Stock Exchange under the ticker
symbol ICX.L and on the Open Market and the Xetra trading platform
of the Frankfurt Stock Exchange under the symbol
IGJ.F.
Corporate fact
sheet
|
|
|
| Home · Disclaimer ·
Privacy Statement · Site Map |